British-Swedish pharmaceutical company AstraZeneca said the number of blood clots among the 17 million people who received the vaccine is «lower than would be expected in the general population.»
«About 17 million people in the EU and the UK have received our vaccine, and the number of reported cases of blood clots is lower than the hundreds of cases that would be expected in the general population,» said Anne Taylor, head of the company’s medical department.
AstraZeneca also said that there is no evidence of an increased risk of blood clots from the drug. According to the company, there are currently only 15 cases of deep vein thrombosis and 22 cases of pulmonary embolism in the EU and the UK. In addition, during clinical trials, the number of cases of blood clots was lower in the group that received the vaccine.
Видите беспорядок или несправедливость в своём районе? Не проходите мимо! Присылайте нам фото, видео или новости в наш Telegram-чат. Ваши новости помогают нам отслеживать нарушения и информировать жителей вовремя.